Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT05695222

Cutaneous Squamous Cell Carcinoma Staging Study

Cutaneous Squamous Cell Carcinoma Staging Study — Recruiting • Oncology • NCT05695222.

📅 02 Apr 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT05695222
Start
2023-05-01
Completion
2028-06-05
ClinicaliQ Trial Snapshot
  • Cutaneous Squamous Cell Carcinoma Staging Study — Recruiting • Oncology • NCT05695222.
  • Review the linked registry entry for study design, population, endpoints, and operational status.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Cutaneous squamous cell carcinoma (CSCC) is the second most common form of skin cancer, and one of the most common cancers worldwide. The majority of CSCCs are easily removed by surgery and have excellent prognosis. However, a small subset has poor outcomes, including secondary spread in the body (metastasis) and death. The investigators will look at existing CSCC in people from two UK dermatology centres. The investigators will then evaluate the accuracy of current staging systems in predicting risk of poor outcomes in people. The investigators hope that this project…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Guideline
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Oncology · 16 Jun 2026
First-line treatment option: Cemiplimab combined with platinum-based chemotherapy is recommended by NICE for patients with untreated advanced non-small-cell lung cancer (NSCLC), offering…
View guideline →
Guideline
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Oncology · 09 Jul 2026
Cemiplimab is recommended as a treatment option for patients with recurrent or metastatic cervical cancer only after progression on or following platinum-based…
View guideline →
Guideline
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Oncology · 26 Aug 2026
Test for MSI-H/dMMR before treatment: All patients with advanced or recurrent endometrial cancer should undergo microsatellite instability or mismatch repair deficiency testing…
View guideline →
Guideline
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
Oncology · 19 Aug 2026
First-line treatment option: Acalabrutinib combined with bendamustine and rituximab is recommended as a first-line treatment for untreated mantle cell lymphoma, offering an…
View guideline →
Guideline
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Oncology · 18 Jun 2026
Serplulimab combined with carboplatin and etoposide is recommended as first-line treatment for untreated extensive-stage small-cell lung cancer (ES-SCLC) and should be considered…
View guideline →